BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 16525582)

  • 1. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).
    Takada Y
    J Biomed Biotechnol; 2012; 2012():136302. PubMed ID: 23125522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins.
    Kwak SH; Mitra S; Bdeir K; Strassheim D; Park JS; Kim JY; Idell S; Cines D; Abraham E
    J Leukoc Biol; 2005 Oct; 78(4):937-45. PubMed ID: 16033814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
    Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V
    J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
    Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
    Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1).
    Bass R; Ellis V
    Thromb Haemost; 2009 May; 101(5):954-62. PubMed ID: 19404550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
    O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
    Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
    Pluskota E; Soloviev DA; Plow EF
    Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
    Kim KS; Hong YK; Joe YA; Lee Y; Shin JY; Park HE; Lee IH; Lee SY; Kang DK; Chang SI; Chung SI
    J Biol Chem; 2003 Mar; 278(13):11449-56. PubMed ID: 12529357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin alpha(v)beta(3), metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect.
    Maupas-Schwalm F; Bedel A; Augé N; Grazide MH; Mucher E; Thiers JC; Salvayre R; Nègre-Salvayre A
    Cell Signal; 2009 Dec; 21(12):1925-34. PubMed ID: 19735728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
    Ellis V
    J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M; Goretzki L; Pfeifer M; Mueller BM
    Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
    Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
    J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.